METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oral testosterone regimen shows promise in advanced prostate cancer trial
Disease control CompletedThis study tested a new way to give testosterone therapy to men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. Instead of injections, patients took oral testosterone for seven days, then stopped for seven days, repeating this cycle. I…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Immune priming therapy shows promise in tough prostate cancer
Disease control CompletedThis early-phase study tested a new cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The treatment aims to boost the body's natural killer cells to fight the cancer. Researchers looked for the safest and most effectiv…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New hope for Hard-to-Treat prostate cancer: early trial shows promise
Disease control CompletedThis early-stage study tested a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. All participants had …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New prostate cancer drug tested in china: safety first
Disease control CompletedThis early-stage study tested a new drug called MK-5684 in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal was to check the drug's safety and how the body processes it, not to prove it works. Participants t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New cocktail of immune drugs shows promise against tough prostate cancer
Disease control CompletedThis study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received one of three drug combinations. The goal was to see if the treatments could shrink tumors or lower PSA le…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control CompletedThis study tested a new drug called vudalimab, alone or with standard treatments, in 72 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the drug is safe and can shrink tumors or lower PSA levels. Participants had to have cancer…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Patients choose: which chemo is easier to tolerate?
Symptom relief CompletedThis study asked men with advanced prostate cancer which of two standard chemotherapies they preferred based on side effects and overall experience. Each patient tried both treatments in sequence and then stated their preference. The goal is to help doctors choose the best first-…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated May 13, 2026 16:03 UTC
-
Prostate cancer drug Radium-223 under safety microscope in 1,472-Patient study
Knowledge-focused CompletedThis study looked at the long-term safety of Radium-223 in 1,472 men with metastatic castration-resistant prostate cancer. Researchers tracked side effects, bone marrow problems, and the risk of developing new cancers after treatment. The goal was to understand the drug's safety …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 17, 2026 03:01 UTC
-
New PET scan could help track prostate cancer treatment success
Knowledge-focused CompletedThis study looked at whether a special PET scan (18F-fluciclovine) can show how well treatments are working in men with advanced prostate cancer that no longer responds to hormone therapy. Nine men were given standard treatments like abiraterone, enzalutamide, or docetaxel. The P…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC